Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome?

Journal of Endocrinological Investigation

Volumn 26, Issue 8, 2003, Pages 710-717

  Uwaifo, G I ^a   Koch, C A ^a   Hirshberg, B ^b   Chen, C C ^c   Hartzband, P ^d   Nieman, L K ^a   Pacak, K ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NIDDK   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Ectopic ACTH syndrome; Neuroendocrine tumors; Radionuclide imaging; Somatostasin analogs; Somatostatin receptors

Indexed keywords

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CORTICOTROPIN; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MITOTANE; OCTREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ADRENALECTOMY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARCINOID; CASE REPORT; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DISEASE CONTROL; DOSE CALCULATION; DROWSINESS; DRUG EFFECT; DRUG RESPONSE; DRUG WITHDRAWAL; ECTOPIC CORTICOTROPIN PRODUCTION; FATTY LIVER; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOKALEMIA; IMAGING; LIVER DYSFUNCTION; LONG TERM CARE; LYMPH NODE DISSECTION; MAINTENANCE DRUG DOSE; MALE; MONITORING; PHARMACODYNAMICS; PREDICTION; PROVOCATION TEST; SCINTIGRAPHY; STEROIDOGENESIS; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT FAILURE; WEIGHT GAIN;

EID: 0344876173     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347351     Document Type: Article

References (45)

1. Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 2000, 85: 42-7.
2. Watson RG, Van Heerden JA, Northcutt RC, Grant CS, Ilstrup DM. Results of adrenal surgery for Cushing's syndrome: 10 years' experience. World J Surg 1986, 10: 531-8.
3. Koch CA, Doppman JL, Watson JC, Patronas NJ, Nieman LK. Spinal epidural lipomatosis in a patient with the ectopic corticotropin syndrome. N Engl J Med 1999, 341: 1399-400.
4. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 2001, 86: 4104-8.
5. Von Werder K, Muller OA, Stalla GK. Somatostatin analogs in ectopic corticotropin production. Metabolism 1996, 45: 129-31.
6. 111In-DTPA-D-Phe1] octreotide. Postgrad Med J 1998, 74: 108-10.
7. Kristoffersson A, Olsson T, Bjornebrink J, Hagg E. Diagnosis of ectopic ACTH production from a bronchial carcinoid by imaging with octreotide scintigraphy. Eur J Surg 1996, 162: 515-8.
8. Christin-Maitre S, Chabbert-Buffet N, Mure A, Boukhris R, Bouchard P. Use of somatostatin analog for localization and treatment of ACTH secreting bronchial carcinoid tumor. Chest 1996, 109: 845-6.
9. 111indium-DTPA labelled octreotide. Clin Endocrinol (Oxf) 1995, 43: 763-7.
10. Phlipponneau M, Nocaudie M, Epelbaum J, et al. Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 1994, 78: 20-4.
11. Oliaro A, Filosso PL, Casadio C, et al. Bronchial carcinoid associated with Cushing's syndrome. J Cardiovasc Surg 1995, 36: 511-4.
12. De Herder WW, Krenning EP, Malchoff CD, et al. Somatostatin receptor scintigraphy: Its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 1994, 96: 305-12.
13. Tabarin A, Valli N, Chanson P, et al. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999, 84: 1193-202.
14. 111Inpentetreotide scintigraphy in localizing ectopic ACTH producing tumors: Follow-up of 18 patients. J Clin Endocrinol Metab 1999, 84: 1186-92.
15. De Herder WW, Lamberts SW. Is there a role for somatostatin and its analogs in Cushing's syndrome? Metabolism 1996, 45: 83-5.
16. Suzuki S, Hashizume K, Kobayashi M, et al. Somatostatin analogue (SMS 201-995) decreases plasma levels of corticotropin (ACTH) and corticotropin-releasing hormone in a patient with ectopic ACTH-producing tumors. Endocrinol Jpn 1990, 37: 923-32.
17. Van Den Bruel A, Bex M, Van Dorpe J, Heyns W, Bouillon R. Occult ectopic ACTH secretion due to recurrent lung carcinoid: Long-term control of hypercortisolism by continuous subcutaneous infusion of octreotide. Clin Endocrinol (Oxf) 1998, 49: 541-6.
18. De Rosa G, Testa A, Liberale I, Pirronti T, Granone P, Picciocchi A. Successful treatment of ectopic Cushing's syndrome with the long-acting somatostatin analog octreotide. Exp Clin Endocrinol 1993, 101: 319-25.
19. Cheung NW, Boyages SC. Failure of somatostatin analogue to control Cushing's syndrome in 2 cases of ACTH-producting carcinoid tumours. Clin Endocrinol (Oxf) 1992, 36: 361-7.
20. Woodhouse NJ, Dagogo-Jack S, Ahmed M, Judzewitsch R. Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome. Am J Med 1993; 95: 305-8.
21. Rieu M, Rosilio M, Richard A, Vannetzel JM, Kuhn JM. Paradoxical effect of somatostatin analogues on the ectopic secretion of corticotropin in 2 cases of small cell lung carcinoma. Horm Res 1993; 39: 207-12.
22. Duquenne M, Dousset B, Weryha G, et al. Paradoxical effect of octreotide in neoplastic inappropriate corticotropin secretion. Lancet 1991, 338: 1407-8.
23. Chan NN, Isaacs AJ. Lack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma. Postgrad Med J 1999, 75: 96-7.
24. Diez J, Iglesias P. Successful treatment of ectopic Cushing's syndrome with the slow release somatostatin analog lanreotide: Case report. The Endocrinologist 1999, 9: 399-402.
25. Parthiban A, Sundaram DS, Reddy DJ, Girinath MR, Prabhakaran R, Chidambaranathan N. Octreotide and ketoconazole for persistent ectopic ACTH Cushing's disease due to mediastinal carcinoid. J Assoc Physicians India 1995, 43: 140.
26. Kornely E, Schlaghecke R, Horster FA. Palliative therapy of an ectopic Cushing's syndrome due to a metastatic carcinoid tumor. Klin Wochenschr 1991; 69: 173-6.
27. Gill GV, Young A, Power E, Ramage J. Carcinoid-associated ectopic ACTH syndrome with variable response to octreotide. Postgrad Med J 1999, 75: 98-100.
28. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998, 19: 647-72.
29. Koch CA, Azumi N, Furlong MA, et al. Carcinoid syndrome caused by an atypical carcinoid of the uterine cervix. J Clin Endocrinol Metab 1999, 84: 4209-13.
30. De Herder WW, Lamberts SW. Tumor localization - The ectopic ACTH syndrome. J Clin Endocrinol Metab 1999, 84: 1184-5.
31. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993; 60: 245-64.
32. Bruns C, Weckbecker G, Raulf F, Lubbert H, Hoyer D. Characterization of somatostatin receptor subtypes. Ciba Found Symp 1995, 190: 89-101.
33. De Herder WW, Hofland LJ, Van Der Lely AJ, Lamberts SW. Peptide receptors in gut endocrine tumours. Baillieres Clin Gastroenterol 1996, 10: 571-87.
34. Hofland LJ, Lamberts SW. Somatostatin receptors and disease: Role of receptor subtypes. Baillieres Clin Endocrinol Metab 1996, 10: 173-76.
35. Hofland LJ, Visser-Wisselaar HA, Lamberts SW. Somatostatin analogs: Clinical application in relation to human somatostatin receptor subtypes. Biochem Pharmacol 1995, 50: 287-97.
36. Lichtenauer-Kaligis EG, Van Hagen PM, Lamberts SW, Hofland LJ. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 2000, 143 (Suppl 1): S21-5.
37. Ferone D, Van Hagen PM, Colao A, Annunziato L, Lamberts SW, Hofland LJ. Somatostatin receptors in the thymus. Ann Med 1999, 31 (Suppl 2): 28-33.
38. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: Recent advances and potential relevance. Yale J Biol Med 1997, 70: 471-9.
39. Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994, 733: 122-37.
40. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, Degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab 2001; 86: 2161-9.
41. Reubi JC, Kvols L, Krenning E, Lamberts SW. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990; 39: 78-81.
42. De Herder WW, Van Der Lely AJ, Lamberts SW. Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J 1996, 72: 403-8.
43. Lamberts SW, De Herder WW, Van Koetsveld PM, et al. Somatostatin receptors: Clinical implications for endocrinology and oncology. Ciba Found Symp 1995, 190: 222-36.
44. James RA. Octreotide and ectopic Cushing's syndrome - A commentary. Clin Endocrinol (Oxf) 1998; 49: 419-20.
45. Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 1990; 13: 257-61.